A selective thyroid hormone receptor beta agonist demonstrated dose-dependent reductions in hepatic fat among adults with metabolic dysfunction-associated steatohepatitis, with higher doses achieving reductions exceeding 30% compared with placebo.
Medscape Medical News
Source link
Headlines
